Linking adipose tissue eosinophils, IL-4, and leptin in human obesity and insulin resistance
JCI Insight · 08.02.2024 · 9 (3)
DOI: 10.1172/jci.insight.170772 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 08.02.2024. Verfasst von James D Hernandez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Research, Allied Health, Mayo Clinic Arizona, Scottsdale, Arizona, USA. Hauptthemen laut MEDLINE: Insulin Resistance, Leptin. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCATS NIH HHS, NIH HHS.
Abstract (Originalsprache)
BACKGROUND Obesity is a multifactorial disease with adverse health implications including insulin resistance (IR). In patients with obesity, the presence of high circulating levels of leptin, deemed hyperleptinemia, is associated with IR. Recent data in mice with diet-induced obesity (DIO) show that a partial reduction in leptin levels improves IR. Additional animal studies demonstrate that IL-4 decreases leptin levels. In rodents, resident adipose tissue eosinophils (AT-EOS) are the main source of IL-4 and are instrumental in maintaining metabolic homeostasis. A marked reduction in AT-EOS content is observed in animal models of DIO. These observations have not been explored in humans. METHODS We analyzed AT from individuals with obesity and age-matched lean counterparts for AT-EOS content, IL-4, circulating leptin levels, and measures of IR. RESULTS Our results show that individuals with obesity ( n = 15) had a significant reduction in AT-EOS content ( P < 0.01), decreased AT–IL-4 gene expression ( P = 0.02), and decreased IL-4 plasma levels ( P < 0.05) in addition to expected IR ( P < 0.001) and hyperleptinemia ( P < 0.01) compared with lean subjects ( n = 15). AT-EOS content inversely correlated with BMI ( P = 0.002) and IR ( P = 0.005). Ex vivo AT explants and in vitro cell culture of primary human mature adipocytes exposed to either IL-4 or EOS conditioned media produced less leptin ( P < 0.05). CONCLUSION Our results suggest that IL-4 acts as a link between EOS, AT, and leptin production. Future studies exploring this interaction may identify an avenue for the treatment of obesity and its complications through amelioration of hyperleptinemia. TRIAL REGISTRATION Clinicaltrials.gov NCT02378077 & NCT04234295.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Research, Allied Health, Mayo Clinic Arizona, Scottsdale, Arizona, USA.
- Arizona State University, Barrett, The Honors College, Tempe, Arizona, USA.
- Mayo Clinic Graduate School.
- Division of General Surgery.
- Division of Allergy, Asthma, and Clinical Immunology, and.
- Division of Endocrinology and Metabolism, Mayo Clinic Arizona, Scottsdale, Arizona, USA.
Förderung
- NIAID NIH HHS
- NCATS NIH HHS
- NIH HHS
- NCAT/NIH
- NIAID
- Mayo Foundation for Medical Education and Research
- Arizona Biomedical Research Commission
- Katryn H. and Roger Penske Career Development Award in Endocrinology in Honor of Dr. Ian Hay
Zitieren
APA
Hernandez, J. D., Li, T., Ghannam, H., Rau, C. M., Masuda, M. Y., Madura, J. A., Jacobsen, E. A., & De Filippis, E. (2024). Linking adipose tissue eosinophils, IL-4, and leptin in human obesity and insulin resistance. JCI Insight, 9(3). https://doi.org/10.1172/jci.insight.170772
Vancouver
Hernandez JD, Li T, Ghannam H, Rau CM, Masuda MY, Madura JA, et al. Linking adipose tissue eosinophils, IL-4, and leptin in human obesity and insulin resistance. JCI Insight. 2024;9(3). doi:10.1172/jci.insight.170772
BibTeX
@article{Hernandez2024,
author = {Hernandez, James D and Li, Ting and Ghannam, Hamza and Rau, Cassandra M and Masuda, Mia Y and Madura, James A and Jacobsen, Elizabeth A and De Filippis, Eleanna},
title = {Linking adipose tissue eosinophils, IL-4, and leptin in human obesity and insulin resistance},
journal = {JCI Insight},
year = {2024},
volume = {9},
number = {3},
doi = {10.1172/jci.insight.170772}
}
EUVIMED